Iovance Biotherapeutics, Inc. (IOVA) News
Track canonical SquawkNews coverage tagged to IOVA, Iovance Biotherapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 19 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
IOVA - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
IOVA - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
NEWS | Sep 18, 2026, 09:10 PM UTC
M
IOVA jumps 21% in four sessions as Barclays cites upside
IOVance Biotherapeutics (IOVA) shares have risen more than 21% over the past four sessions. Barclays expects the rally to continue as investors await an important lung cancer update; stock was up nearly 2% in pre-market
EQUITY | Sep 17, 2026, 11:59 AM UTC
M
Iovance says clear line of sight to profitability
Iovance Biotherapeutics says record Amtagvi sales underpin a “clear line of sight to profitability” as it prepares for year-end data and trial updates.
EQUITY | Sep 15, 2026, 11:01 PM UTC
L
Biotech Stocks At 52-Week Highs - NUTX +8%, IOVA +7%, ATRC, CNC, CON
WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 15, 2026, driven by the gain on certain clinical or financial results.Nutex Health Inc. (NUTX)Nutex Health functions as a healthcare
EARNINGS | Sep 15, 2026, 07:40 AM UTC
L
Iovance Biotherapeutics to present at upcoming conferences
Iovance Biotherapeutics announced that senior leadership will present at upcoming conferences.
EQUITY | Sep 04, 2026, 12:07 PM UTC
L
IOVA - Iovance Biotherapeutics to Present at Upcoming Conferences
IOVA - Iovance Biotherapeutics to Present at Upcoming Conferences
EQUITY | Sep 04, 2026, 12:00 PM UTC
L
Iovance Biotherapeutics reports inducement grants under NASDAQ Rule 5635(c)(4)
Iovance Biotherapeutics (IOVA) reports inducement grants issued under NASDAQ Listing Rule 5635(c)(4), according to the company filing referenced by TradeXchange Newsdesk.
REGULATION | Aug 21, 2026, 09:15 PM UTC
L
IOVA highs +12%
IOVA highs +12%
EQUITY | Aug 20, 2026, 06:55 PM UTC
H
Iovance Biotherapeutics trades at 52-week high after sector-linked momentum
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is trading at a 52-week high despite no company-specific news, while the post also cites second-quarter results and reaffirmed fiscal 2026 sales guidance.
EARNINGS | Aug 20, 2026, 05:14 PM UTC
L
BAP BILL CPB IOVA JKHY MRK MRNA MRVL NU SJM TGT TJX TOL ZM LOW MAR PT changes @ UBS
BAP BILL CPB IOVA JKHY MRK MRNA MRVL NU SJM TGT TJX TOL ZM LOW MAR PT changes @ UBS
EQUITY | Aug 20, 2026, 11:04 AM UTC
H
IOVA rallies to highs, +13.75% above $8
IOVA trades at new highs, up 13.75% above $8 to its best level since December 2024, according to Hammerstone MarketTalk.
EQUITY | Aug 19, 2026, 07:40 PM UTC
L
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results
Iovance Biotherapeutics Inc (NASDAQ: IOVA ) shares are surging Thursday after the cancer therapy company beat second-quarter expectations on both the top and bottom lines. Here’s what you should know. Iovance Biotherapeu
EARNINGS | Aug 06, 2026, 06:06 PM UTC
H
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Motorola Solutions In c (NYSE: MSI ) rose sharply after the company reported better-than-expected second-quarter financial
EARNINGS | Aug 06, 2026, 02:01 PM UTC
L
Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $350.000M-$370.000M vs $362.083M Est
Iovance Biotherapeutics (NASDAQ: IOVA ) affirms FY2026 sales outlook from $350.000 million-$370.000 million to $350.000 million-$370.000 million vs $362.083 million estimate.
EARNINGS | Aug 06, 2026, 11:11 AM UTC
H
Iovance Biotherapeutics Reports Record Revenue
Iovance reports $99M revenue in Q2 2026
EQUITY | Aug 06, 2026, 11:01 AM UTC
H
IOVA falls 8.4% on REPL melanoma treatment
IOVA shares drop on competing treatment news
EQUITY | Jul 31, 2026, 02:38 PM UTC
L
IOVA - Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 - Click For
IOVA - Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
EARNINGS | Jul 30, 2026, 12:00 PM UTC
M
BIVI Files $300M Mixed Shelf
BIVI and other companies file mixed shelf offerings with the SEC
EQUITY | Jun 22, 2026, 09:29 AM UTC
L
IOVA Files Mixed Shelf
IOVA files a mixed shelf offering with the SEC
EQUITY | Jun 18, 2026, 08:32 PM UTC